Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Cancer: early-phase trial registry
45 of 123 indexed Advanced Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #97 of 28,707 conditions by registered trial count.
123 US clinical trials · 45 currently recruiting · #97 of 28,707 conditions by registered trial count
Advanced Cancer: 123 US clinical trials tracked, 45 recruiting.
Advanced Cancer is the subject of 123 registered US clinical trials on ClinicalTrials.gov, 45 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 85 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 19 of these trials.
Enrollment posture brief
Registry condition advanced-cancer
OPEN 45 | RECR 37% | LATE 2 | EARLY 85 | RANK #97 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Type 2 Diabetes (37% recruiting · 328 trials)
Advanced Cancer lists 45 open slots (37% of 123 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Cancer recruits in line with its size-band peers.
45 of 123 indexed trials (36.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Advanced Cancer research.
M.D. Anderson Cancer Center accounts for 19 of 123 trials (15.4%). 79 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 123 trials that report a genuine target (sentinel values excluded). 65 of those (52.8%) plan for fewer than 100 participants.
-
Advanced Cancer research is mostly interventional.
112 interventional and 11 observational studies make up this index (91.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
123 total, page 3 of 3
Feasibility, Acceptability and Preliminary Effects of the Spiritual Care Assessment and Intervention
Indiana University
NCT03823313
Safety Study of FP-1039 To Treat Cancer
Five Prime Therapeutics
NCT00687505
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Mast Therapeutics
NCT00664170
A Trial of ZL-1201 in Subjects With Advanced Cancer
Zai Lab (Shanghai) Co.
NCT04257617
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
TaiRx
NCT02507544
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
University of Alabama at Birmingham
NCT03137121
A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer
Alaunos Therapeutics
NCT00421135
Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors
Alaunos Therapeutics
NCT00608803
A Dose-Escalation Study in Participants With Advanced Cancer
Eli Lilly and Company
NCT01524224
A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors
Celldex Therapeutics
NCT02642016
Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer
CASI pharmaceuticals
NCT00408226
Telephone-Based Mindfulness CBT for Patients in Community Settings With Advanced Cancer
Duke University
NCT03285633
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
Astellas Pharma Global Development
NCT04837196
A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors
Processa Pharmaceuticals
NCT04861987
Behavioral Activation-Led Activity Engagement for Cancer Empowerment
University of Pittsburgh
NCT06796608
DM-CHOC-PEN for Brain Tumors in AYA Subjects
DEKK-TEC
NCT03668847
DM-CHOC-PEN Plus Radiation for Brain Tumors
DEKK-TEC
NCT03371004
Temsirolimus In Phase 0
M.D. Anderson Cancer Center
NCT01417065
An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advance Refractory Cancer
Scottsdale Healthcare
NCT01443390
STAMP+CBT mHealth for Cancer Pain
Dana-Farber Cancer Institute
NCT05403801
The Science of the Art of Palliative Care
Dartmouth-Hitchcock Medical Center
NCT05137782
FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib
M.D. Anderson Cancer Center
NCT01143779
Collaborative Care Intervention for Cancer Caregivers
University of Pittsburgh
NCT02944136
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 71 |
| Phase 2 | 14 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Cancer page
123 registered trials, 45 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 45 Advanced Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Advanced Cancer trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Cancer condition card totals 123 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.